Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 29;13(5):367.
doi: 10.3390/pathogens13050367.

HBV and HCV Co-Infection in Chinese Newly Diagnosed HIV+ Subjects in 2015 and 2023: A Cross-Sectional Study

Fangyuan Li  1 , Yi Feng  1 , Xiu Liu  1 , Jingjing Hao  1 , Dong Wang  1 , Hongping Hu  1 , Chang Song  1 , Jing Hu  1 , Quanbi Zhao  1 , Hua Liang  1 , Lingjie Liao  1 , Yuhua Ruan  1 , Hui Xing  1
Affiliations

HBV and HCV Co-Infection in Chinese Newly Diagnosed HIV+ Subjects in 2015 and 2023: A Cross-Sectional Study

Fangyuan Li et al. Pathogens. .

Abstract

With shared routes of transmission, HBV and HCV co-infection are estimated to occur more in subjects with HIV. This study aimed to characterize and describe the prevalence of HBV and HCV co-infections in a cohort of newly diagnosed HIV+ subjects living in China. We conducted a cross-sectional study among newly diagnosed HIV+ subjects aged 18-100 who participated in surveys on the national HIV molecular epidemiology in 2015 and 2023. (The epidemiological table survey is located in the national database alongside serologic testing). The chi-square test was used to identify changes in infections between the studying populations in 2015 and 2023, and conditional logistic regression models were fit to identify risk factors for each co-infection. Among the 11,024 newly diagnosed HIV+ subjects who were surveyed (n = 4501 in 2015; n = 6523 in 2023), the prevalence of HBV, HCV, and HBV/HCV in 2023 was lower than that in 2015, respectively. No decrease was observed in HCV co-infection in men who had sex with men (MSM) in North China, Northeast China, and East China. Increasing recognition among those at high risk of heterosexual transmission and those with low educational backgrounds is paramount to the prevention and control of HIV/HBV/HCV infections.

Keywords: HBV; HCV; HIV; co-infection; infection route.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
HBV (left) and HCV (right) co-infection in newly diagnosed HIV-infected patients with different transmission routes in 2015 (red) and 2023 (grey). Note: others include modes of transmission such as mother-to-child transmission and lack of information. p values were calculated using the chi-square test. p values < 0.05 are statistically significant.
Figure 2
Figure 2
HBV and HCV co-infection in newly diagnosed HIV-infected patients in different regions in 2015 (red) and 2023 (grey). Note: The colors represent 2015 or 2023, and p values were calculated using the chi-square test. p values < 0.05 are statistically significant. North provinces: Beijing (BJ), Tianjin (TJ), Hebei (HE), Shanxi (SX), and Inner Mongolia Autonomous Region (NM). Northeast provinces: Liaoning (LN), Jilin (JL), and Heilongjiang (HLJ). Eastern provinces: Shanghai (SH), Jiangsu (JS), Zhejiang (ZJ), Jiangxi (JX), Anhui (AH), Fujian (FJ), and Shandong (SD). Central provinces: Henan (HA), Hubei (HB), and Hunan (HN). Southern provinces: Guangdong (GD), Guangxi Zhuang Autonomous Region (GX), and Hainan (HI). Southwest provinces: Chongqing (CQ), Sichuan (SC), Guizhou (GZ), Yunnan (YN), and Tibet Autonomous Region (XZ). Northwest provinces: Shaanxi (SN), Gansu (GS), Qinghai (QH), Ningxia Hui Autonomous Region (NX), and Xinjiang Uygur Autonomous Region (XJ).
See this image and copyright information in PMC

References

    1. NCAIDS/STD National AIDS Venereal Disease in the Second Quarter of 2023. J. China AIDS Sex Transm. Dis. 2023;29:953. (In Chinese)
    1. Razavi-Shearer D., Gamkrelidze I., Pan C., Jia J., Berg T., Gray R., Lim Y.S., Chen C.J., Ocama P., Desalegn H., et al. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: A modelling study. Lancet Gastroenterol. Hepatol. 2023;8:879–907. doi: 10.1016/S2468-1253(23)00197-8. - DOI - PubMed
    1. Blach S., Terrault N.A., Tacke F., Gamkrelidze I., Craxi A., Tanaka J., Waked I., Dore G.J., Abbas Z., Abdallah A.R., et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modeling study. Lancet Gastroenterol. Hepatol. 2022;7:396–415. doi: 10.1016/S2468-1253(21)00472-6. - DOI - PubMed
    1. Deng H., Deng X., Liu Y., Xu Y., Lan Y., Gao M., Xu M., Gao H., Wu X., Liao B., et al. Naturally occurring antiviral drug resistance in HIV patients who are mono-infected or co-infected with HBV or HCV in China. J. Med. Virol. 2018;90:1246–1256. doi: 10.1002/jmv.25078. - DOI - PubMed
    1. Gobran S.T., Ancuta P., Shoukry N.H. A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection. Front. Immunol. 2021;12:726419. doi: 10.3389/fimmu.2021.726419. - DOI - PMC - PubMed

MeSH terms